Free Trial
→ This stock has 30 days of quiet left (From Behind the Markets) (Ad)tc pixel Free TTOO Stock Alerts

T2 Biosystems (TTOO) Competitors

T2 Biosystems logo
$0.0002 0.00 (0.00%)
As of 05/22/2026 02:15 PM Eastern
Compare

TTOO vs. WOK, SDCCQ, GMVDF, VRAYQ, and AFIB

Should you buy T2 Biosystems stock or one of its competitors? MarketBeat compares T2 Biosystems with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with T2 Biosystems include WORK Medical Technology Group (WOK), SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), ViewRay (VRAYQ), and Acutus Medical (AFIB). These companies are all part of the "medical equipment" industry.

How does T2 Biosystems compare to WORK Medical Technology Group?

T2 Biosystems (NASDAQ:TTOO) and WORK Medical Technology Group (NASDAQ:WOK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
T2 Biosystems
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
WORK Medical Technology Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

T2 Biosystems has a beta of 8.21, indicating that its stock price is 721% more volatile than the broader market. Comparatively, WORK Medical Technology Group has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market.

In the previous week, T2 Biosystems had 2 more articles in the media than WORK Medical Technology Group. MarketBeat recorded 2 mentions for T2 Biosystems and 0 mentions for WORK Medical Technology Group. T2 Biosystems' average media sentiment score of 0.00 equaled WORK Medical Technology Group'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
WORK Medical Technology Group Neutral

WORK Medical Technology Group has higher revenue and earnings than T2 Biosystems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
WORK Medical Technology Group$9.81M0.00-$1.07MN/AN/A

23.2% of T2 Biosystems shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

WORK Medical Technology Group has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
WORK Medical Technology Group N/A N/A N/A

Summary

T2 Biosystems and WORK Medical Technology Group tied by winning 5 of the 10 factors compared between the two stocks.

How does T2 Biosystems compare to SmileDirectClub?

SmileDirectClub (NASDAQ:SDCCQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

In the previous week, T2 Biosystems had 2 more articles in the media than SmileDirectClub. MarketBeat recorded 2 mentions for T2 Biosystems and 0 mentions for SmileDirectClub. SmileDirectClub's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
SmileDirectClub Neutral
T2 Biosystems Neutral

SmileDirectClub has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 8.21, suggesting that its share price is 721% more volatile than the broader market.

T2 Biosystems has lower revenue, but higher earnings than SmileDirectClub. T2 Biosystems is trading at a lower price-to-earnings ratio than SmileDirectClub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SmileDirectClub$470.74M0.00-$86.40M-$0.29N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

SmileDirectClub has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
SmileDirectClubN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

0.1% of SmileDirectClub shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 64.7% of SmileDirectClub shares are held by insiders. Comparatively, 0.0% of T2 Biosystems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

SmileDirectClub and T2 Biosystems tied by winning 5 of the 10 factors compared between the two stocks.

How does T2 Biosystems compare to G Medical Innovations?

G Medical Innovations (NASDAQ:GMVDF) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

6.0% of G Medical Innovations shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 37.1% of G Medical Innovations shares are owned by company insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

G Medical Innovations has a beta of 30.95, meaning that its share price is 2,995% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 8.21, meaning that its share price is 721% more volatile than the broader market.

In the previous week, T2 Biosystems had 2 more articles in the media than G Medical Innovations. MarketBeat recorded 2 mentions for T2 Biosystems and 0 mentions for G Medical Innovations. G Medical Innovations' average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
G Medical Innovations Neutral
T2 Biosystems Neutral

G Medical Innovations has higher earnings, but lower revenue than T2 Biosystems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G Medical Innovations$4.42M0.00-$24.63MN/AN/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

G Medical Innovations has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
G Medical InnovationsN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

Summary

G Medical Innovations beats T2 Biosystems on 5 of the 8 factors compared between the two stocks.

How does T2 Biosystems compare to ViewRay?

T2 Biosystems (NASDAQ:TTOO) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 0.0% of T2 Biosystems shares are owned by company insiders. Comparatively, 2.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

T2 Biosystems has a beta of 8.21, suggesting that its share price is 721% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

In the previous week, T2 Biosystems had 2 more articles in the media than ViewRay. MarketBeat recorded 2 mentions for T2 Biosystems and 0 mentions for ViewRay. T2 Biosystems' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
ViewRay Neutral

T2 Biosystems has higher earnings, but lower revenue than ViewRay. T2 Biosystems is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
ViewRay N/A N/A N/A

Summary

T2 Biosystems and ViewRay tied by winning 5 of the 10 factors compared between the two stocks.

How does T2 Biosystems compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

T2 Biosystems has higher revenue and earnings than Acutus Medical. Acutus Medical is trading at a lower price-to-earnings ratio than T2 Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

In the previous week, T2 Biosystems had 2 more articles in the media than Acutus Medical. MarketBeat recorded 2 mentions for T2 Biosystems and 0 mentions for Acutus Medical. Acutus Medical's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
T2 Biosystems Neutral

56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Acutus Medical has a beta of 6.08, suggesting that its share price is 508% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 8.21, suggesting that its share price is 721% more volatile than the broader market.

Acutus Medical has a net margin of -272.74% compared to T2 Biosystems' net margin of -563.16%. T2 Biosystems' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
T2 Biosystems -563.16%N/A -174.06%

Summary

T2 Biosystems beats Acutus Medical on 7 of the 12 factors compared between the two stocks.

Get T2 Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTOO vs. The Competition

Export
MetricT2 BiosystemsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$4K$53.33M$6.46B$12.34B
Dividend YieldN/A1.08%2.76%5.28%
P/E Ratio0.0018.6821.2225.65
Price / Sales0.0037.51553.9286.28
Price / CashN/A18.8743.4956.67
Price / Book0.0016.1510.377.14
Net Income-$50.08M-$20.25M$3.57B$335.98M
7 Day PerformanceN/A2.27%6.40%4.15%
1 Month PerformanceN/A-12.00%3.52%2.54%
1 Year PerformanceN/A-2.39%34.02%35.05%

T2 Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TTOO
T2 Biosystems
N/A$0.00
flat		N/A-99.9%$4K$7.68MN/A180
WOK
WORK Medical Technology Group
0.7867 of 5 stars		$6.66
+69.9%		N/A-100.0%$67K$9.81MN/A226
SDCCQ
SmileDirectClub
N/A$0.00
-90.0%		N/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/A$0.00
-50.0%		N/AN/A$26K$4.42MN/A72
VRAYQ
ViewRay
N/AN/AN/AN/A$18K$102.21MN/A300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TTOO) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel